Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of "Buy" by Analysts

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has been given a consensus rating of "Buy" by the six ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $16.75.

A number of brokerages recently issued reports on ZURA. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zura Bio in a research report on Friday, October 18th. Piper Sandler reissued an "overweight" rating and issued a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. Leerink Partners assumed coverage on shares of Zura Bio in a report on Monday. They issued an "outperform" rating and a $15.00 price target on the stock. HC Wainwright reissued a "neutral" rating and issued a $5.00 price target on shares of Zura Bio in a report on Monday, October 21st. Finally, Leerink Partnrs raised shares of Zura Bio to a "strong-buy" rating in a report on Monday.

Zura Bio Trading Down 5.9 %

ZURA stock traded down $0.26 on Tuesday, reaching $4.11. 424,386 shares of the company were exchanged, compared to its average volume of 324,888. Zura Bio has a 12 month low of $2.00 and a 12 month high of $6.35. The stock's fifty day moving average price is $4.17 and its 200 day moving average price is $4.09.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.02). As a group, sell-side analysts predict that Zura Bio will post -0.47 EPS for the current year.

Insider Transactions at Zura Bio

In other news, Director Someit Sidhu sold 51,728 shares of the company's stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the sale, the director now owns 2,085,418 shares of the company's stock, valued at approximately $8,070,567.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 22.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. acquired a new position in Zura Bio during the 2nd quarter worth about $8,446,000. Armistice Capital LLC lifted its position in Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company's stock worth $8,834,000 after buying an additional 876,000 shares in the last quarter. Great Point Partners LLC lifted its position in Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company's stock worth $16,248,000 after buying an additional 1,884,501 shares in the last quarter. Forefront Analytics LLC lifted its position in Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company's stock worth $145,000 after buying an additional 7,531 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new position in Zura Bio during the 2nd quarter worth about $43,000. Institutional investors and hedge funds own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.